Open | - |
Close | - |
Volume / Avg. | 0 / 271.114K |
Day Range | - - - |
52 Wk Range | 13.360 - 27.500 |
Market Cap | $620.101M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 43 |
Short Interest | 24.68% |
Days to Cover | 22.46 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of AnaptysBio (NASDAQ: ANAB) through any online brokerage.
Other companies in AnaptysBio’s space includes: Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Larimar Therapeutics (NASDAQ:LRMR), Fate Therapeutics (NASDAQ:FATE) and Cullinan Oncology (NASDAQ:CGEM).
The latest price target for AnaptysBio (NASDAQ: ANAB) was reported by Wedbush on Tuesday, March 12, 2024. The analyst firm set a price target for 0.00 expecting ANAB to fall to within 12 months (a possible -100.00% downside). 12 analyst firms have reported ratings in the last year.
The stock price for AnaptysBio (NASDAQ: ANAB) is $23.17 last updated March 18, 2024 at 4:00 PM EDT.
There are no upcoming dividends for AnaptysBio.
AnaptysBio’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for AnaptysBio.
AnaptysBio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.